Low Fructose

Phase 1Small molecule

JJason Winnick

Low Fructose is one of 42 small molecule programs targeting Hypoglycemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoglycemiaActive, not recruiting

HypoglycemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

77 competitors in Hypoglycemia

#DrugCompanyPhaseTrials

NOVOLIN R

Novo Nordisk

Approved

1 2

Narcan

SScienture

Approved

2 3

Glucagon

XXeris Pharmaceuticals

Phase 3

14 4

Ilaris

Novartis

Phase 3

1 5

Zegalogue

Zealand Pharma

Phase 3

4 6

Jardiance

Boehringer Ingelheim

Phase 3

3 7

Sandostatin

Sun Pharma

Phase 3

2 8

Glibenclamide

Novo Nordisk

Phase 3

1 9

MS Contin

Merck & Co.

Phase 2

1 10

Elavil

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Active, not recruiting

Hypoglycemia

NCT03241706

Clinical

Trials by Indication[1]

Hypoglycemia1 trial

Liver Glycogen and Hypoglycemia in Humans

Active, not recruiting·JJason Winnick·Phase 1·NCT03241706·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Low Fructose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low Fructose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low Fructose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jason Winnick company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: JJason Winnick

Low Fructose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Hypoglycemia1 trial

References

Drug Info

Quick Facts

Related News